The Bridge

BridgeBio is a commercial-stage biopharmaceutical company focused on developing medicines for genetic conditions and genetically defined cancers. The company uses a decentralized hub-and-spoke operating model, branded internally as "The Bridge Way," to advance multiple programs in parallel while centralizing clinical, regulatory, and commercial capabilities. Its marketed products include Attruby (acoramidis) for transthyretin amyloid cardiomyopathy and NULIBRY (fosdenopterin) for molybdenum cofactor deficiency type A. BridgeBio's late-stage pipeline includes BBP-418 for limb-girdle muscular dystrophy type 2I/R9, encaleret for autosomal dominant hypocalcemia type 1 and chronic hypoparathyroidism, and infigratinib for skeletal dysplasias such as achondroplasia. The company also maintains gene therapy and oncology efforts, including BBP-812 for Canavan disease and a newly disclosed TTR amyloid depleter antibody program.